Research & Education

Radiation Webinar - Making Progress in Stage III NSCLC Management

Thursday, July 9, 2015 - 6 p.m. AEST / 10 a.m. CEST - Recording Available

The IASLC Education Committee is pleased to announce the continuation of a series of Live Webinars presented by the Advanced Radiation Technology Committee. This subcommittee is focused on providing educational and informational programs addressing state of the art radiation therapy for lung cancer. This live program will be moderated by Francoise Mornex, MD, PhD and feature presentations by Professor David Ball and Professor Michael Mac Manus.

Françoise MORNEX David Ball Michael MacManus 

Program Chair
PR Françoise Mornex , MD, PhD

Département de Radiothérapie
Centre Hospitalier Lyon Sud
LYON, France

Professor David Ball

Deputy Director, Radiation
Oncology & Cancer Imaging
Chair, Lung Service

Professor Michael MacManus

Radiation Oncologist
Peter MacCallum Cancer Centre
East Melbourne Australia and
The Sir Peter MacCallum
Department of Oncology
University of Melbourne

Name of Reviewer(s): 


Fred Hirsch, MD, PhD –Speakers Bureau/Advisory Board: Astrazeneca, Genentech, BMS, Lilly and Abbvie.

Name of Planner(s): 


     Deb Whippen-Nothing to Disclose

Name of Activity: 


Making Progress in Stage III NSCLC Management

Date of Activity:






PR Françoise Mornex , MD, PhD-Moderator-Consulting for: Lilly, Roche and Boehringrt-Ingelheim

Professor David Ball MB BS, MD, FRANZCR-Speaker- Nothing to Disclose

Professor Michael MacManus MD MRCP FRANZCR-Speaker- Nothing to Disclose

Franco Foti-Moderator- Nothing to Disclose

Type of Activity: 

 Live Course

  Internet Live Course (Webinar)XXXX

 Internet Enduring Material

Are there Commercial Supporters for this activity?


If yes, please list: Unrestricted grant from: Elekta

The Place of PET CT for Diagnosis and Treatment - Prof. Michael MacManus

In this presentation, the role of PET/CT in the diagnosis, staging, biological characterization and therapeutic response assessment of NSCLC will be considered. The importance of molecular imaging for selection of patients for curative intent treatment with surgery or radiation therapy will be reviewed as will be the advances made in the use of PET/CT for radiation treatment planning.

Early Response Assessment and Opportunities for Adaptive Radiotherapy - Prof. David Ball

This presentation will review the anatomical and metabolic changes which can be detected in the tumor and normal tissues during a six week course of radiotherapy. It will also address how this information can be used to adapt the radiotherapy to create a personalized prescription.

After attending this session attendees will:

  • Demonstrate when to order a PET/CT scan
  • Illustrate how to use the information obtained from PET/CT scans in everyday clinical practice
  • Review radiotherapy for an individual patient and create a personalized prescription

Following the presentations there will be ample opportunity for the audience to submit questions and comments to the faculty via internet chat.


CME Information:

Financial/Commercial Relationships DISCLOSURES

A Conflict of Interest (COI) is created and exists when individuals in a position to control the content of CME, or their spouses/partners, that have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells, or distributes health care goods or services consumed by, or used, on patients that benefits the individual in any financial amount and therefore, may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected. 

 This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

IASLC CME assures that the planners/reviewers/authors/faculty/moderators/peer reviewers et. al. conflicts of interest  were identified, reviewed and resolved from all individuals involved in the development  or able to influence and control the content of this CME activity; IASLC CME assures that disclosure is given prior to an educational activity being delivered to learners.  Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from any of IASLC CME activity presentation.

All commercial relationships and conflicts of interest that are identified are thoroughly vetted by IASLC Ethics Committee, CME Subcommittee, and Independent reviewer. COI will be evaluated by the Board of Directors of the IASLC for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. IASLC CME is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.


IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This presentation will review the anatomical and metabolic changes which can be detected in the tumor and normal tissues during a six week course of radiotherapy. It will also address how this information can be used to adapt the radiotherapy to create a personalized prescription.


This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Thank you for your participation.

Download Recording

IASLC Financial/Commercial Relationships and Conflicts of Interest Policy

IASLC Honorarium Policy

IASLC Financial/Commercial Relationships Agreement (LOA)

Participants who complete a pre-and post-test along with an evaluation will receive 1 AMA PRA Category 1 CreditTM for each completed webinar.  

If you are interested in obtaining the CME Credits for these sessions you must indicate this when you register for the program. CME Credit is only available for those that participate in the Live Session.

This live webinar series is designed to meet the educational needs of radiation oncologists, medical oncologists, thoracic surgeons, radiologists, pathologists, and advanced practice nurses, physician's assistants and other healthcare professionals who diagnose and treat patients with lung cancer.

Location Local time Time zone UTC offset
New York (U.S.A. - New York) Thursday, July 9, 2015 at 4:00:00 AM EDT UTC-4 hours
Melbourne (Australia - Victoria) Thursday, July 9, 2015 at 6:00:00 PM AEST UTC+10 hours
Tokyo (Japan) Thursday, July 9, 2015 at 5:00:00 PM JST UTC+9 hours
Beijing (China - Beijing Municipality) Thursday, July 9, 2015 at 4:00:00 PM CST UTC+8 hours
Bangkok (Thailand) Thursday, July 9, 2015 at 3:00:00 PM ICT UTC+7 hours
Seoul (South Korea) Thursday, July 9, 2015 at 5:00:00 PM KST UTC+9 hours
Paris (France) Thursday, July 9, 2015 at 10:00:00 AM CEST UTC+2 hours
London (United Kingdom - England) Thursday, July 9, 2015 at 9:00:00 AM BST UTC+1 hour
Corresponding UTC (GMT) Thursday, July 9, 2015 at 08:00:00    

How to use the Time Zone Converter

This series is partially supported by an unrestricted grant from Varian Medical Systems, Inc., Elekta, and Accuray